• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Healthcare

Cramer: Here's the Reason for Allergan's Remarkable Run

Static doesn't work in this industry. Pipelines work.
By JIM CRAMER Feb 09, 2017 | 06:12 AM EST
Stocks quotes in this article: AGN, MRK, PFE, GILD, REGN

Allergan (AGN) sounded like Merck (MRK) and Pfizer (PFE) . No not this Merck or Pfizer, but the ones from the old days, when you barely wanted to hear about the old drugs -- you knew they were making good money. You wanted to hear about the new drugs, the ones that would conquer heart disease or nerve damage or cholesterol. You wanted to hear about innovation, not price increases.

Action Alerts PLUS charity portfolio holding Allergan is the reincarnation of those companies. Sure, it is true that Allergan's labs, while productive, aren't the source of the big drugs that CEO Brent Saunders is talking about. That comes from acquisitions of little companies that Brent understands to have something special. He might get criticized for paying too much for a small-cap company, but then again, what did Gilead (GILD) do to get into the Hepatitis C segment? It spent $11 billion, an 89% premium, to acquire Pharmasset, which had a promising potential cure for the often fatal disease.

It's more important now than ever to return to the old model of growth because, for example, if you have the real breakthrough drug for depression, one that can impact the level, say, of suicides, then you have something that you can charge a lot more for rather than trying to ratchet up prices for old drugs, which had become the habit for the marketing machine pharmas that used to be the places of great invention.

Brent says he has a drug with that kind of potential. He also thinks he has something for macular degeneration that would make it so you only need to be shot in the eye every 12 weeks, instead of once in a month which is the current standard of care that Regeneron's (REGN) Eylea provides. Finally, he has a drug for NASH, non-alcoholic liver disease, which is a very big market but a tough one to date to figure out.

If you want to know why Allergan was up so much yesterday, just go look at why Gilead was down so much. Gilead owned the hepatitis C cure business, but ended up with some competitors that have brought the price down, while at the same time the drug is not a maintenance drug -- it is a cure. So it sows the seeds of its own destruction. All the way down from the hundreds, most investors thought that Gilead would do what Brent did, find companies that have a compelling pipeline -- big or small -- to give us a future reason to stay long the stock.

Gilead didn't; 18 months ago this stock was at $117, now it is as $66. It could have easily gone the way of Allergan, which has now moved from $180 to $241 and I think is headed a lot higher, because it is cheaper than all major pharma companies but has a faster growth rate.

It chose to be static.

Static doesn't work in this industry. Pipelines do. Allergan's got one, and that's the real reason for this remarkable run after being in the drug dust bin for more than a year.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Action Alerts PLUS, which Cramer co-manages as a charitable trust, is long AGN.

TAGS: Investing | U.S. Equity | Healthcare | Markets | Drug Approvals | How-to | Jim Cramer | Risk Management | Stocks

More from Healthcare

Bearish Bets: 3 Stocks You Should Consider Shorting This Week

Bob Lang
Jul 3, 2022 10:30 AM EDT

These recently downgraded names are displaying both quantitative and technical deterioration.

Nuvalent Has Begun the Bottoming Process

Bruce Kamich
Jul 1, 2022 10:52 AM EDT

Let's check the charts and indicators.

CRISPR Therapeutics Has Turned the Corner

Bruce Kamich
Jul 1, 2022 8:43 AM EDT

Here's our current price target.

Johnson & Johnson Appears to Be Running Out of Steam

Bruce Kamich
Jun 22, 2022 8:25 AM EDT

The shares of the healthcare giant have been in a long-term uptrend but could break that trend in the weeks ahead.

Anthem's Long-Term Uptrend Is Losing Its Vigor

Bruce Kamich
Jun 22, 2022 7:40 AM EDT

The technical signals of the health benefits provider are weakening.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 12:01 PM EDT PAUL PRICE

    A Recent Director Buy in Children's Place (PLCE)

    Four of the most recent insider trades in Children...
  • 07:34 AM EDT PAUL PRICE

    A $525,000 Vote of Confidence on Macerich (MAC)

  • 09:49 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    Stop Wishing, Hoping, and Praying and Take Control...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login